TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18561722

Group type: EXPERIMENTAL
Intervention: 2 g/day purified omega-3 fatty acids
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15757934

Group type: EXPERIMENTAL
Intervention: Genetic testing for Alzheimer's disease (APOE genotype disclosure)
Number of subjects: 148

Group type: COMPARATOR
Intervention: No genetic testing (Control group)
Number of subjects: 148
Study: 11803070

Group type: EXPERIMENTAL
Intervention: 0.5ml (15.5 microg of each HA antigen) dose of the trivalent inactivated influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.25ml (7.75 microg of each HA antigen) dose of the trivalent inactivated influenza vaccine
Number of subjects: 0
Study: 10357750

Group type: EXPERIMENTAL
Intervention: 50 mg vitamin E
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 100 mg vitamin E
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 7948266

Group type: EXPERIMENTAL
Intervention: Icodextrin (glucose polymer) used in peritoneal dialysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Automated peritoneal dialysis regimens with icodextrin
Number of subjects: 0
Study: 3127028

Group type: EXPERIMENTAL
Intervention: Estrogen therapy (Premarin, 1.25 mg/day)
Number of subjects: 21
Study: 31954575

Group type: EXPERIMENTAL
Intervention: High starch textured starter (45% starch) blended with 5% chopped hay fed free choice
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Low starch pelleted starter (8% starch) fed at a rate up to 2.3 kg of dry matter (DM)/d with free‐choice long grass hay
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Ad libitum access to a blend of 95% high starch textured starter (42% starch) and 5% chopped grass hay
Number of subjects: 96

Group type: COMPARATOR
Intervention: High starch textured starter fed up to 2.7 kg of DM/d with free-choice long grass hay
Number of subjects: 96
Study: 30610781

Group type: EXPERIMENTAL
Intervention: Concomitant paclitaxel plus gemcitabine (6 cycles)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sequential paclitaxel followed by gemcitabine (4 cycles each)
Number of subjects: 66
Study: 28515196

Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered cognitive behaviour therapy (ICBT) for 12 weeks
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-delivered cognitive behaviour therapy (ICBT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 67
Study: 25069908

Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 42
Study: 22763161

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 25 (LM25)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Basal insulin glargine (GL)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 193
Study: 19717480

Group type: EXPERIMENTAL
Intervention: P(ET,CO(2)) >or=36 mmHg
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: P(ET,CO(2)) in patients with PE
Number of subjects: 298

Group type: COMPARATOR
Intervention: P(ET,CO(2)) in patients without PE
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Combination of P(ET,CO(2)) >or=36 mmHg with Wells score <4
Number of subjects: 298
Study: 17267222

Group type: COMPARATOR
Intervention: Control foot orthotics (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Grid foot orthotics (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dimple foot orthotics (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Plain foot orthotics (n=10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All conditions (Control, Grid, Dimple, Plain)
Number of subjects: 40
Study: 15966880

Group type: EXPERIMENTAL
Intervention: Single-visit full-mouth ultrasonic debridement with povidone iodine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Single-visit full-mouth ultrasonic debridement with water
Number of subjects: 36

Group type: COMPARATOR
Intervention: Quadrant-wise ultrasonic debridement
Number of subjects: 36
Study: 12204666

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with a three-field technique (35% of cases)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy with a four-field pelvic box technique (65% of cases)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Total radiation dose of 44.7 Gy with a standard deviation of 4.6 Gy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clinical target volume (CTV) drawn on CT scan
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recommendations provided during the trial
Number of subjects: 60
Study: 11379854

Group type: EXPERIMENTAL
Intervention: 1% amino acid‐based PD solution buffered with bicarbonate (Amino/Bic)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1.5% glucose anhydrous‐containing bicarbonate‐buffered solution (Glu/Bic)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1.5% glucose anhydrous‐based dialysis solution with lactate (Glu/Lac)
Number of subjects: 10
Study: 8842579

Group type: EXPERIMENTAL
Intervention: Improved metabolic control
Number of subjects: 35
Study: 1505090

Group type: EXPERIMENTAL
Intervention: Calcium sodium alginate (Kaltostat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trousered paraffin gauze
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glove finger packs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All packing materials
Number of subjects: 0
Study: 6489417

Group type: EXPERIMENTAL
Intervention: Activated charcoal 2.5 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Activated charcoal 10 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Activated charcoal 25 g
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Activated charcoal 50 g
Number of subjects: 6

Group type: COMPARATOR
Intervention: Water 300 ml only
Number of subjects: 6
Study: 31345985

Group type: EXPERIMENTAL
Intervention: Reflective learning framework and toolkit for healthcare staff
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous patient and relative survey and annual staff survey
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitated iterative co-design process
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Locally-adaptable workplace-based toolkit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: National cluster randomised step-wedge trial of the toolkit
Number of subjects: 0
Study: 29552921

Group type: EXPERIMENTAL
Intervention: Prolonged restraint (24-hour short-arm restraint device)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Manual restraint (intermittent holding restraint during therapy)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison of prolonged restraint vs manual restraint
Number of subjects: 62
Study: 26807637

Group type: EXPERIMENTAL
Intervention: CUSA group (n = 24)
Number of subjects: 45

Group type: COMPARATOR
Intervention: non-CUSA group (n = 21)
Number of subjects: 45
Study: 24417482

Group type: EXPERIMENTAL
Intervention: Anger-framed message
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Sadness-framed message
Number of subjects: 115

Group type: COMPARATOR
Intervention: No emotion-framed message
Number of subjects: 115
Study: 22244160

Group type: EXPERIMENTAL
Intervention: TACE plus intravenous bevacizumab (10 mg/kg IV every 14 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Observation (TACE-O)
Number of subjects: 30

Group type: COMPARATOR
Intervention: TACE-O
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TACE-BEV
Number of subjects: 30
Study: 19414843

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 0
Study: 17460134

Group type: EXPERIMENTAL
Intervention: Provider Feedback
Number of subjects: 913

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 913
Study: 16022847

Group type: EXPERIMENTAL
Intervention: 20 microg of ethinylestradiol and 100 microg of levonorgestrel
Number of subjects: 48

Group type: COMPARATOR
Intervention: 30 microg of ethinylestradiol and 150 microg of levonorgestrel
Number of subjects: 48
Study: 12243438

Group type: EXPERIMENTAL
Intervention: Topical application of 1.25 x 10(6) KIU aprotinin (4 doses)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Systemic application of 5 x 10(6) KIU aprotinin
Number of subjects: 97
Study: 9951268

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of midazolam (mdz) using a nasal route
Number of subjects: 248

Group type: COMPARATOR
Intervention: 0.2 mg/kg of diazepam (dz) per os 45' before induction
Number of subjects: 248
Study: 7616634

Group type: EXPERIMENTAL
Intervention: Pelvic plus para‐aortic irradiation
Number of subjects: 367

Group type: COMPARATOR
Intervention: Pelvic only irradiation
Number of subjects: 367
Study: 2340945

Group type: EXPERIMENTAL
Intervention: 80 mg furosemide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25 mg hydrochlorothiazide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg flosequinan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg flosequinan
Number of subjects: 0
Study: 6948488

Group type: EXPERIMENTAL
Intervention: Intra-articular injections of a mixture of corticosteroid and local anaesthetic, given once a week for three weeks.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Occlusal treatment including splints, grinding on natural teeth, and occlusal correction of complete dentures.
Number of subjects: 33
Study: 30557792

Group type: EXPERIMENTAL
Intervention: Ramucirumab with or without paclitaxel
Number of subjects: 989

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 989
Study: 28679342

Group type: EXPERIMENTAL
Intervention: Percutaneous laser disc decompression (PLDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional surgery (microdiscectomy)
Number of subjects: 0
Study: 25381096

Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with preventive swallowing rehabilitation
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Acoustic voice analysis
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Subjective vocal function (VHI score)
Number of subjects: 22
Study: 24400639

Group type: EXPERIMENTAL
Intervention: Corneal A501D IOL
Number of subjects: 62

Group type: COMPARATOR
Intervention: Corneal J501D IOL
Number of subjects: 62
Study: 21955098

Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Ustekinumab (both doses)
Number of subjects: 158
Study: 19597387

Group type: EXPERIMENTAL
Intervention: Cisplatin-based adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualized adjuvant chemotherapy (discussed conceptually)
Number of subjects: 0
Study: 17990228

Group type: EXPERIMENTAL
Intervention: Amodiaquine plus sulfadoxine-pyrimethamine
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 559
Study: 15887503

Group type: EXPERIMENTAL
Intervention: Fluor Protector (0.1% fluoride)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Cervitec (1% chlorhexidine and 1% thymol)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Fluor Protector and Cervitec
Number of subjects: 19
Study: 12034583

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 22071
Study: 9579121

Group type: EXPERIMENTAL
Intervention: Full angioscopic preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angioscopy and histology evaluation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Harvested vein in organ culture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angioscopy
Number of subjects: 0
Study: 7647691

Group type: EXPERIMENTAL
Intervention: Fish oil (4.4 g n-3 fatty acids/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Corn oil supplements
Number of subjects: 12
Study: 2699556

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Trazodone
Number of subjects: 27
Study: 799558

Group type: EXPERIMENTAL
Intervention: Oxprenolol alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phentolamine with oxprenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Labetalol (400 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phentolamine alone
Number of subjects: 0
Study: 31441836

Group type: EXPERIMENTAL
Intervention: TXA + Dexa (10 mg Dexa just after anesthesia and repeated at 24 hours post-surgery)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: TXA + Dexa
Number of subjects: 88

Group type: COMPARATOR
Intervention: TXA
Number of subjects: 88
Study: 28384006

Group type: EXPERIMENTAL
Intervention: Mind-body intervention (3-day residential course + two 8-hour follow-up events)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mind-body intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 30
Study: 26055067

Group type: EXPERIMENTAL
Intervention: Baseline FGF21 levels
Number of subjects: 9697

Group type: EXPERIMENTAL
Intervention: Addition of FGF21 levels in a model of new on‐study total microvascular disease with established risk factors
Number of subjects: 9697
Study: 23075691

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 35

Group type: COMPARATOR
Intervention: PI/r
Number of subjects: 35
Study: 21770241

Group type: EXPERIMENTAL
Intervention: Tang-shen-fang (TSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 19338427

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg
Number of subjects: 1132

Group type: EXPERIMENTAL
Intervention: Zoledronic acid 5 mg (third injection)
Number of subjects: 1132
Study: 17375491

Group type: EXPERIMENTAL
Intervention: Intervention (details not provided)
Number of subjects: 0
Study: 15515413

Group type: EXPERIMENTAL
Intervention: Local injections of tropisetron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical application of local anaesthetics combined with depot corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Local injection of prilocaine
Number of subjects: 0
Study: 11718981

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stress Reducing Strategies (SRS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Psychological support interventions (both hypnosis and SRS)
Number of subjects: 30
Study: 9399390

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily
Number of subjects: 535

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg at night
Number of subjects: 535

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study: 8476803

Group type: EXPERIMENTAL
Intervention: Routine Doppler ultrasound
Number of subjects: 2025

Group type: COMPARATOR
Intervention: Highly selective use of Doppler ultrasound
Number of subjects: 2025
Study: 3624684

Group type: EXPERIMENTAL
Intervention: Aerosolized atropine (1.5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Aerosolized lidocaine (80 to 160 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Oral indomethacin (50 mg three times daily for 10 doses)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Aerosolized phosphate-buffered saline
Number of subjects: 6
Study: 30999881

Group type: EXPERIMENTAL
Intervention: 8-month intervention including written materials, videos, peer support coaching, and group meetings focused on nutrition and physical activity.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8-month intervention materials focused on nutrition and physical activity best practices.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group receiving group meetings focused on reading readiness.
Number of subjects: 0
Study: 30039161

Group type: EXPERIMENTAL
Intervention: Postdischarge telephone call within 4 days of discharge
Number of subjects: 966

Group type: COMPARATOR
Intervention: Standard discharge
Number of subjects: 966
Study: 27849355

Group type: EXPERIMENTAL
Intervention: Acute cocoa flavanol (903 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cognitive Task (CT) post-exercise
Number of subjects: 12
Study: 24859364

Group type: EXPERIMENTAL
Intervention: Imatinib treatment with BCR-ABL1 halving time <76 days (n = 74)
Number of subjects: 528

Group type: COMPARATOR
Intervention: Imatinib treatment with BCR-ABL1 values not halving by 76 days (n = 21)
Number of subjects: 528
Study: 22949275

Group type: EXPERIMENTAL
Intervention: Evidence-based interventions implemented by an interdisciplinary rehabilitation team
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (35 patients discharged before implementation)
Number of subjects: 35
Study: 20394488

Group type: EXPERIMENTAL
Intervention: High-quality skin cream
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream vehicle
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Emollient oil
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cold cream emulsion
Number of subjects: 4

Group type: COMPARATOR
Intervention: Untreated skin (control)
Number of subjects: 4
Study: 18028577

Group type: EXPERIMENTAL
Intervention: Opioid-free continuous psoas compartment block with 0.75% ropivacaine (0.4 mL kg(‐1) loading dose followed by 10 mL h(‐1) of 0.2% ropivacaine for 48 hours)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intravenous infusion of 0.1% morphine and 0.12% ketorolac at 2 mL h(‐1) for 48 hours
Number of subjects: 73
Study: 16210049

Group type: EXPERIMENTAL
Intervention: Combination therapy (desloratadine 5 mg + montelukast 10 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 12371974

Group type: EXPERIMENTAL
Intervention: Standardized treatment after biopsy
Number of subjects: 96
Study: 9925057

Group type: EXPERIMENTAL
Intervention: RIF under fasting conditions
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: RIF with aluminum‐magnesium antacid
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: RIF with high‐fat meal
Number of subjects: 14
Study: 7579503

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen (TAM) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No systemic adjuvant therapy (Control)
Number of subjects: 0
Study: 1703024

Group type: EXPERIMENTAL
Intervention: Non-mydriatic Polaroid retinal photography
Number of subjects: 2159

Group type: COMPARATOR
Intervention: Ophthalmoscopy with mydriasis
Number of subjects: 2159
Study: 7208246

Group type: EXPERIMENTAL
Intervention: Positive reinforcement (Group 1): Subjects were shown a highly preferred slide following each correct detection.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Knowledge of results (Group 2): Subjects received a second, longer presentation of every item responded to and every critical one omitted.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Practice control (Group 3): Subjects faced a blank screen during inter-stimulus intervals.
Number of subjects: 24
Study: 31005171

Group type: EXPERIMENTAL
Intervention: Pre-operative breast MRI
Number of subjects: 210
Study: 27072796

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment recommendation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment recommendation in psychiatric university hospital
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic treatment recommendation for patients with F2 diagnosis
Number of subjects: 100
Study: 26363840

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 601

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 601
Study: 23290428

Group type: EXPERIMENTAL
Intervention: Misoprostol plus Isosorbide Mononitrate (IMN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Misoprostol (control group)
Number of subjects: 0
Study: 21453919

Group type: EXPERIMENTAL
Intervention: Protocol driven, nurse‐initiated discharge
Number of subjects: 131

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study: 19583673

Group type: EXPERIMENTAL
Intervention: Pharmacist-physician co-managed programme
Number of subjects: 118

Group type: COMPARATOR
Intervention: Routine conventional care (Control)
Number of subjects: 118
Study: 17158523

Group type: EXPERIMENTAL
Intervention: Combined antithrombotic therapy (antiplatelet plus moderate-level anticoagulant)
Number of subjects: 967

Group type: COMPARATOR
Intervention: Anticoagulant therapy alone
Number of subjects: 967
Study: 15093869

Group type: EXPERIMENTAL
Intervention: Mild MR
Number of subjects: 2082

Group type: EXPERIMENTAL
Intervention: Moderate/severe MR
Number of subjects: 2082

Group type: COMPARATOR
Intervention: No MR
Number of subjects: 2082
Study: 11707791

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia at T11 sensory level
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control without anesthesia
Number of subjects: 8
Study: 8958162

Group type: EXPERIMENTAL
Intervention: L-Arginine (1 g, two daily dosages)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: L-Arginine (after crossover)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (after crossover)
Number of subjects: 30
Study: 8023026

Group type: EXPERIMENTAL
Intervention: Experimental treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatments
Number of subjects: 0
Study: 3125029

Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 51
Study: 29033108

Group type: EXPERIMENTAL
Intervention: Conservative management
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional medical therapy
Number of subjects: 130
Study: 27650228

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control (nonsupplemented group)
Number of subjects: 196
Study: 24783622

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.02 microg x kg(-1) x min(-1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40